24/7 Market News Snapshot 27 February, 2025 – Heron Therapeutics, Inc. (NASDAQ:HRTX)

February 27, 2025

DENVER, Colo., 27 February, 2025 (247marketnews.com) – (Nasdaq:HRTX) are discussed in this article.
Heron Therapeutics, Inc. (Nasdaq:HRTX) is experiencing noteworthy momentum, as evidenced by its stock price which opened at $1.89 and surged by 20.17% to reach $2.055, following a previous close of $1.71. This considerable increase highlights heightened investor confidence and interest in the company, with trading volumes reaching 5.88 million shares. This bullish sentiment aligns with the company’s impressive financial outcomes for the year.

In its recent financial report, Heron announced a GAAP net income of $3.6 million for the fourth quarter of 2024, contributing to a total net revenue of $144.2 million for the year—a 14% increase from the prior year. Notably, the company recorded $8.5 million in net revenue from ZYNRELEF® in Q4 2024, bolstered by the launch of the ZYNRELEF Vial Access Needle in December. The updated indications for ZYNRELEF position it to cover approximately 17 million targeted surgical procedures annually, showcasing its expansive potential in postoperative pain management.

Craig Collard, Chief Executive Officer, remarked on the transformative year for Heron, emphasizing a strategic focus that yielded strong financial results and set the groundwork for future growth. Recent regulatory approvals and strategic partnerships are expected to enhance ZYNRELEF’s market reach.

Moreover, Heron achieved a favorable legal outcome in a patent lawsuit against Fresenius Kabi USA, confirming the validity of its CINVANTI® patents until 2035, further solidifying its competitive stance in the oncology market. Looking ahead, the company anticipates net revenues between $153 million and $163 million for 2025, along with an adjusted EBITDA projected to reach up to $8 million. With an emphasis on patient-centric innovations, Heron Therapeutics is poised for sustained success in the forthcoming year.

Related news for (HRTX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.